Compensated Awareness Post View
Disclaimer
Curis, Inc. (CRIS) Developing Pipeline of Innovative Treatment Options Addressing Human Cancers
Curis is a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment of human cancers. The company’s leading product candidate, CUDC-907, is currently in phase I clinical trials for the treatment of lymphoma and multiple myeloma, as well as solid tumors. Additionally, the company’s product pipeline includes CUDC-427, which is being studied for the treatment of solid tumors and lymphomas, and CUDC-305 for the treatment of cancers.
The company’s most advanced drug, Erivedge®, was developed in collaboration with Genentech, Inc. and is currently approved for use in patients with advanced basal cell carcinoma (BCC) in the United States, the European Union, Australia and a collection of other countries. The potential market for Erivedge is extensive. According to a report by the Skin Cancer Foundation, an estimated 2.8 million patients in the U.S. are diagnosed with BCC annually, making it the most common form of skin cancer. In the first quarter of 2015, Curis recorded $1.7 million in royalty revenues from global sales of the product, representing a 30 percent year-over-year improvement.
In recent months, Curis has made significant progress toward the continued expansion of its promising product pipeline. In January, the company entered into an exclusive collaboration agreement with Aurigene Discovery Technologies Limited focused on the discovery, development and commercialization of small molecule immuno-oncology therapeutics. In the months to come, Curis will have the option to exercise exclusive licensing rights on a selection of drug candidates already in clinical development, providing a platform for strong financial growth.
With an established and growing presence in the immuno-oncology treatment industry, Curis has access to near limitless market potential moving forward. According to investment bank Leerink Swann, the immuno-oncology market is expected to reach a value of approximately $29 billion within the next decade, potentially revolutionizing the treatment options for a wide variety of cancer types along the way.
For prospective investors, Curis’s recent clinical progress could foreshadow an opportunity for improved returns in the coming years. Look for the company to leverage the expanding demand for innovative immuno-oncology treatment options in order to promote continued market growth in the future.
For more information, visit www.curis.com
